drugset / Trial / NCT01396161

A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients

NCT01396161

Phase 1 Completed 64 enrolled Pfizer
RandomizedDouble-blindBasic science

Summary

The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-05175157 in healthy volunteers and patients with type 2 diabetes mellitus.

Timeline

Start
2011-07
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05175157 Small molecule 30 mg Oral
Subject PF-05175157 Small molecule 100 mg Oral
Subject PF-05175157 Small molecule 200 mg Oral